Kathleen Goin serves as Chief Operating Officer at Palvella Therapeutics Inc., a clinical-stage biotechnology company dedicated to developing innovative therapies for debilitating rare diseases, with a primary focus on dystrophic epidermolysis bullosa (DEB). In her role, Goin oversees all operational aspects of the company, including clinical development, manufacturing, regulatory affairs, and supply chain management. She plays a pivotal role in advancing Palvella's lead investigational therapy, QX005N, through late-stage clinical trials, ensuring efficient execution of the company's pipeline while fostering strategic partnerships to accelerate patient access to transformative treatments. With over 20 years of experience in the biopharmaceutical industry, Goin brings a proven track record of scaling operations and driving growth in dynamic environments. Prior to joining Palvella, she was Senior Vice President of Corporate Development at Strongbridge Biopharma, where she led key business development initiatives, including strategic alliances and financing efforts that supported the company's portfolio expansion. Earlier in her career, Goin held progressive leadership roles at Endo International plc, rising to Vice President of Finance and Business Operations, where she managed financial planning, mergers and acquisitions, and operational efficiencies across global teams. Goin's notable achievements include orchestrating multimillion-dollar transactions and operational turnarounds that enhanced organizational agility and shareholder value. A graduate of Villanova University with a BS in Accountancy and an MBA from Drexel University, she is recognized for her strategic acumen and commitment to patient-centric innovation, positioning Palvella for sustained success in rare disease therapeutics.